Inhibition of Gal beta1, 4GlcNAc alpha2,6 sialyltransferase expression by antisense-oligodeoxynucleotides.
Treatment of human colorectal carcinoma cells HT29 with specific antisense oligodeoxynucleotides led to a decreased Gal beta1,4GlcNAc alpha2,6 sialyltransferase activity on the level of protein expression as well as on the mRNA level. Antisense treatment did not effect cell viability or cell growth. Oligodeoxynucleotides which were complementary to the region upstream of the initiation codon were particularly effective in inhibition of enzyme expression. No such inhibition was found by treatment of cells with oligodeoxynucleotides complementary to the region downstream of the initiation codon or by treatment of cells with scrambled controls or sense oligodeoxynucleotides.
Kemmner
W
W
Department of Surgical Oncology, Robert-Rössle-Klinik at the Max-Delbrück-Centrum for Molecular Medicine, Berlin, Germany. kemmnerw@rrkchir.mdc-berlin.de
Hohaus
K
K
Schlag
P M
PM
D002455:Cell Division / Q000187:drug effects; D004789:Enzyme Activation / Q000187:drug effects / Q000235:genetics; D019073:HT29 Cells; D006801:Humans; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology*; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D012333:RNA, Messenger / Q000037:antagonists & inhibitors / Q000187:drug effects; D012799:Sialyltransferases / Q000037:antagonists & inhibitors* / Q000096:biosynthesis* / Q000235:genetics; D000094802:beta-D-Galactoside alpha 2-6-Sialyltransferase
D009838:Oligodeoxyribonucleotides; D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger; D012799:Sialyltransferases; D000094802:beta-D-Galactoside alpha 2-6-Sialyltransferase